Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CK Life Sciences Int'l., (Holdings) Inc.
長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 0775)

BUSINESS UPDATE ON PRECLINICAL STUDIES OF CANCER VACCINES AND THE PROGRESS OF RESEARCH COLLABORATION TO DEVELOP AN AI-EMPOWERED CANCER VACCINE PLATFORM

CK Life Sciences Int'l., (Holdings) Inc. (the "Company") announces that the Company will present new data from preclinical studies of investigational cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.

The said cancer vaccines target PRAME (Preferentially Expressed Antigen in Melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3) and Claudin 6 proteins.

PRAME is a protein highly expressed in several cancers, including melanoma, liver cancer and leukemia.

PD-L1 is one of the most important immune checkpoint proteins that is highly expressed in cancer cells to block T cell activation in the tumour microenvironment.

B7-H3 is another immune checkpoint protein that modulates T cell responses and is often overexpressed in cancer.

Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in cancers like breast cancer, lung cancer and endometrial cancer, where it is associated with tumour progression and metastasis.

In addition, the Company will co-present with its research collaborator two posters showcasing their Artificial Intelligence (AI)-empowered platform for designing cancer vaccines at the 2025 AACR Annual Meeting.

The Company is satisfied with the preclinical efficacy results of the investigational cancer vaccines targeting PRAME, PD-L1, B7-H3 and Claudin 6 proteins and hopes to advance these and other vaccines into clinical development in the future. Additionally, the Company is pleased with the progress made in its efforts to develop an AI platform aimed at better predicting immunogenicity and designing cancer vaccines that are more likely to be effective.

The Company is determined to accelerate its R&D. Currently, a number of therapeutic cancer vaccines are in clinical and discovery/preclinical research stages. Amongst them, seviprotimut-L, a cancer vaccine already in the final research stage, is being tested for the adjuvant treatment of stage IIB or IIC melanoma following definitive surgical resection.

It should be noted that the research is only at the preclinical study stage and the Company has not yet commenced clinical trials for these vaccines and accordingly, there is no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 22 April 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).